glp1
Ozempic (semaglutide) tracker
Educational reference for Ozempic (semaglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
165 h
Tmax
24 h
Category
glp1
Also known as: semaglutide-novo
Ozempic is Novo Nordisk's brand of injectable semaglutide marketed for type 2 diabetes.
Mechanism
Ozempic is a brand name for semaglutide, a long-acting GLP-1 receptor agonist. See the semaglutide entry for the full mechanism.
Research summary
Ozempic is the once-weekly injectable semaglutide product approved for type 2 diabetes. For weight management, the semaglutide product Wegovy is used. See the semaglutide entry for trial context (SUSTAIN, cardiovascular outcomes).
Reported side effects
As a semaglutide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the semaglutide entry for details. This is not a complete safety profile.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Ozempic prescribing information · FDA prescribing information (2017)available via DailyMed / accessdata.fda.gov; see semaglutide entry
References
TrackPep er en loggføringsapp. Den registrerer det du logger, og anbefaler eller beregner aldri mengder.